CLINICAL TRIALS PROFILE FOR PREVACID

All Clinical Trials for Prevacid

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00204373 ↗	Treatment of Zollinger-Ellison Syndrome With Prevacid	Completed	Takeda Pharmaceuticals North America, Inc.	Phase 4	2003-03-01	The purpose of this study is to study the safety and efficacy of high dose Prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid.
NCT00204373 ↗	Treatment of Zollinger-Ellison Syndrome With Prevacid	Completed	Charles Mel Wilcox, MD	Phase 4	2003-03-01	The purpose of this study is to study the safety and efficacy of high dose Prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid.
NCT00211614 ↗	Proton Pump Inhibitor Therapy for Mild to Moderate Obstructive Sleep Apnea	Withdrawn	MetroHealth Medical Center	N/A	2006-07-01	Obstructive Sleep Apnea (OSA) is common in modern society, affecting up to 5% of working middle-aged adults in the United States. Obesity is the number one risk factor for the development of OSA. Consequences of untreated OSA are varied and significant and included numerous neuropsychiatric parameters such as mood alterations, depression, anxiety, diminished social interactions, and decreased quality of life. Mounting evidence suggests that treatment of OSA can improve many of these outcomes. The primary treatment modality for this condition is continuous positive airway pressure (CPAP). This device delivers positive pressure to the upper airway in order to prevent its collapse during sleep. Unfortunately, many patients do not choose to use CPAP or have difficulty with these devices. This results in many individuals with OSA either going without therapy or unable to reap the full benefits of treatment. Gastroesophageal reflux (GERD) is also common in the United States and may, in some instances, be directly related to weight gain. Survey studies have suggested that symptomatic GERD is more common in patients with OSA. Whether there exists a cause and effect relationship between these two conditions is not known at present. It has been suggested that GERD may contribute to OSA by narrowing the upper airway. This study will examine the effect of treatment of GERD on mild to moderate OSA. Fifty individuals identified as having mild to moderate OSA (diagnosed by overnight sleep study or PSG) and GERD (confirmed by an esophageal probe) will be enrolled. Both men and women will be included in this study and no "special populations" will be utilized. Subjects will fill out questionnaires to subjectively measure sleepiness, OSA-related symptoms, GERD-related symptoms, and sleep apnea-related quality of life. They will then be randomized to receive either 12 weeks of the proton pump inhibitor lansoprazole (Prevacid) or placebo (twenty five subjects per group). Upon completion of the 12 week trial, subjects will return and the following data will be collected; repeat all of the baseline questionnaires, repeat PSG and repeat pH probe. Results from this study will help to establish the relative effectiveness of a novel form of therapy for a common yet difficult to manage medical condition. . The risks to subjects enrolled in the study are minimal and therefore the benefit to risk ratio is heavily in favor of performing the study.
NCT00215787 ↗	Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease	Completed	Head and Neck Surgery Associates	N/A	2005-09-01	Although nasal polyposis has been recognized as an inflammatory process for many years, the true etiology of nasal polyposis mainly unknown. Despite surgical removal, the recurrence rate after surgery has been reported as high as 87% within the first year after surgery. Anecdotally the Principal Investigator found an incidence of pH probe-proven laryngopharyngeal reflux approaching 80% in his patients with nasal polyposis. Although his number of cases was small, the incidence of recurrence of polyps in these patients was 17%. The PI believes that such an association is too great to be explained by chance alone, and deserves further study. He anticipates two contributions to the literature from this study, the first documenting the incidence of extraesophageal (laryngopharyngeal) reflux in patients with polyposis, and the second showing the impact of reflux treatment on the recurrence rate of the polyps, initially after one year of therapy.
NCT00230516 ↗	Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects	Completed	AstraZeneca	Phase 4	2005-09-01	This study is intended to evaluate whether intravenous (iv) esomeprazole (Nexium® ) offers better intragastric acid suppression than iv lansoprazole (Prevacid ®
NCT00239551 ↗	Effect of Prevacid on Prostaglandin Levels in Patient With Stress Ulcer	Completed	TAP Pharmaceutical Products Inc.	Phase 4	2005-10-01	The purpose of this study is to measure the prostaglandin levels in patients with stress ulcer and the effect of Prevacid on prostaglandin levels in patients with stress ulcer.

Clinical Trial Conditions for Prevacid

Condition Name

Condition Name for Prevacid
Intervention	Trials
Healthy	9
Gastroesophageal Reflux	6
Erosive Esophagitis	4
Asthma	3

Condition MeSH

Condition MeSH for Prevacid
Intervention	Trials
Gastroesophageal Reflux	14
Esophagitis	6
Ulcer	3
Laryngopharyngeal Reflux	3

Clinical Trial Locations for Prevacid

Trials by Country

Trials by Country for Prevacid
Location	Trials
United States	123
China	68
Korea, Republic of	16
Malaysia	12
India	10

Trials by US State

Trials by US State for Prevacid
Location	Trials
Missouri	7
California	7
Florida	6
Pennsylvania	5
Georgia	5

Clinical Trial Progress for Prevacid

Clinical Trial Phase

Clinical Trial Phase for Prevacid
Clinical Trial Phase	Trials
Phase 4	18
Phase 3	8
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Prevacid
Clinical Trial Phase	Trials
Completed	33
Terminated	5
Withdrawn	2

Clinical Trial Sponsors for Prevacid

Sponsor Name

Sponsor Name for Prevacid
Sponsor	Trials
Takeda	8
AstraZeneca	6
TAP Pharmaceutical Products Inc.	6

Sponsor Type

Sponsor Type for Prevacid
Sponsor	Trials
Other	42
Industry	31
NIH	2

Prevacid (Lansoprazole) Clinical Trials, Market Analysis, and Projection

Last updated: February 19, 2026

Prevacid (lansoprazole) is a proton pump inhibitor (PPI) used to treat conditions associated with excess stomach acid. This report analyzes its current clinical trial landscape, market position, and future projections based on patent expirations, generic competition, and emerging therapeutic indications.

What is the Current Status of Prevacid Clinical Trials?

Prevacid's clinical trial activity has significantly decreased due to its mature market status and widespread generic availability. The drug's primary indications are well-established, and new large-scale trials are rare.

• Phase IV (Post-Marketing Studies): Limited Phase IV studies are ongoing, primarily focusing on long-term safety, comparative effectiveness against newer PPIs or H2 blockers in specific patient subgroups, or exploring novel delivery mechanisms. These trials are typically sponsored by generic manufacturers or academic institutions to gather real-world evidence or refine existing product formulations.
• Phase III Trials: No active Phase III trials for novel indications are currently registered for lansoprazole as a monotherapy. The drug's efficacy and safety profile for its approved indications are extensively documented.
• Phase II Trials: Minimal Phase II activity exists, with potential explorations in combination therapies or niche gastrointestinal disorders where a lower-risk, well-understood agent like lansoprazole might be investigated.
• Phase I Trials: There is no active Phase I development for lansoprazole.

The primary driver for any ongoing research is likely the optimization of generic formulations or the investigation of lansoprazole within combination drug regimens for synergistic effects.

What is the Patent Landscape for Prevacid (Lansoprazole)?

The original patents protecting lansoprazole have long since expired, paving the way for extensive generic competition.

• Original Composition of Matter Patent: The primary patent for lansoprazole, US Patent 4,628,098, was granted in 1986 and expired in 2005.
• Formulation and Method of Use Patents: Takeda Pharmaceutical Company, the originator of Prevacid, held various secondary patents covering specific formulations (e.g., orally disintegrating tablets, delayed-release capsules) and methods of use. These patents have also largely expired. For example, patents related to specific dosage forms have expired, with the last significant ones expiring in the early to mid-2010s.
• Exclusivity Periods: Due to patent expirations and Hatch-Waxman Act provisions, the market has been open to generic versions of lansoprazole for over a decade.
• Current Patent Activity: Any remaining patent activity is likely focused on minor formulation improvements, manufacturing processes, or specific polymorphic forms that offer limited, if any, significant therapeutic advantage or market exclusivity extension. These patents are not expected to block the production or sale of existing generic lansoprazole products.

How has the Market for Prevacid Evolved?

The market for Prevacid has undergone significant transformation since its introduction, characterized by initial market dominance followed by rapid erosion due to genericization.

• Peak Sales: Prevacid achieved peak annual sales of over $3 billion in the early 2000s, driven by its efficacy in treating GERD, peptic ulcers, and Zollinger-Ellison syndrome, and robust marketing by Takeda.
• Generic Entry: The expiration of key patents led to the entry of numerous generic lansoprazole manufacturers. This event drastically reduced pricing and market share for the branded product.
• Market Size and Trends: The overall market for PPIs remains large, but the share attributable to branded lansoprazole has diminished substantially. The generic lansoprazole market is highly fragmented and competitive, with pricing dictated by cost-of-goods and volume.
  • Global PPI Market Value (2023 Estimate): Approximately $12-15 billion.
  • Generic Lansoprazole Market Share within PPIs: Estimated to be between 8-12% of the total PPI market value, but a significantly higher percentage in unit volume due to low price points.
• Competitive Landscape: Lansoprazole competes directly with other PPIs (omeprazole, pantoprazole, esomeprazole, rabeprazole) and histamine H2-receptor antagonists (famotidine, ranitidine – though ranitidine has faced significant market withdrawals due to NDMA concerns). Generic lansoprazole competes with generics of these other acid-suppressing agents.
• Pricing Dynamics: Branded Prevacid pricing has been significantly undercut by generic equivalents. A typical monthly supply of generic lansoprazole can range from $10 to $25, depending on the pharmacy and insurance. Branded Prevacid, if still available in limited channels, would command a substantially higher price.
• Physician and Prescriber Behavior: Prescribing patterns have largely shifted to generics due to cost-effectiveness. Physicians generally prescribe lansoprazole (or its generic) when a PPI is indicated, often based on formulary recommendations or patient cost.

What are the Future Projections for Prevacid?

The future of Prevacid, as a branded product, is limited. The generic form will continue to hold a market presence, but its growth potential is constrained by the nature of the generic drug market.

• Branded Prevacid: The branded product is expected to see continued market share decline and negligible sales growth. It will likely remain a niche product for specific institutional contracts or formulary exceptions where slight formulation differences are critical.
• Generic Lansoprazole: The generic lansoprazole market is projected to remain stable in terms of volume, but pricing will likely continue to be suppressed by competition.
  • Volume Growth: Modest volume growth, driven by the aging population and persistent prevalence of GERD and related disorders, is anticipated.
  • Value Growth: Minimal to negative value growth due to intense price competition among manufacturers. The focus for generic companies will be on cost optimization and efficient production.
  • Market Share Stability: Generic lansoprazole is expected to maintain its established share within the broader PPI market, as it is a cost-effective and therapeutically proven option.
• Emerging Opportunities (Limited):
  • Combination Therapies: Lansoprazole may find renewed, albeit small, relevance in novel combination therapies for conditions like Helicobacter pylori eradication or other gastrointestinal infections where synergistic effects are demonstrated. However, this is speculative and would require significant new clinical development.
  • Formulation Innovation (Niche): While major patent-protected innovation is unlikely, minor improvements in delivery (e.g., enhanced taste masking, easier administration for pediatric or elderly populations) by generic manufacturers could sustain demand for specific formulations.
• Threats and Challenges:
  • Competition from Newer Agents: While PPIs are a mature class, research into novel mechanisms for acid suppression or treatment of related disorders continues. However, the barrier to entry for entirely new classes to displace generics like lansoprazole is high.
  • Off-Label Use Scrutiny: Increased regulatory scrutiny and payer restrictions on off-label uses of PPIs could impact overall utilization.
  • Health System Formularies: Continued pressure from payers and health systems to favor the lowest-cost generics will limit any pricing power for any lansoprazole product.
  • NDMA Concerns: While not as prominent as with ranitidine, the broader class of PPIs has faced some scrutiny regarding nitrosamine impurities. Continued monitoring and potential regulatory action could impact market dynamics, though lansoprazole has not been a primary focus of such concerns to date.

Quantitative Market Projections (Generic Lansoprazole):

Metric	2024 (Estimate)	2028 (Projection)	CAGR (2024-2028)	Notes
Global Market	$1.2 - $1.5 Bn	$1.3 - $1.7 Bn	1.0% - 2.5%	Driven by volume increases offset by price erosion.
Unit Volume Growth	2.0% - 3.5%	2.0% - 3.5%	2.0% - 3.5%	Steady demand for cost-effective acid suppression.
Average Price	Declining	Declining	-1.0% to -2.0%	Intense competitive pressure among generic manufacturers.

These projections assume no major unforeseen regulatory actions or significant clinical breakthroughs that would dramatically alter the landscape for PPIs. The market will continue to be characterized by high volume and low margins for generic lansoprazole.

Key Takeaways

• Prevacid (lansoprazole) is a mature pharmaceutical product with expired core patents, leading to widespread generic competition.
• Clinical trial activity for lansoprazole is minimal, primarily confined to post-marketing studies or academic investigations, not novel indications.
• The branded Prevacid market share has significantly eroded, with generic lansoprazole dominating the therapeutic class by volume.
• The generic lansoprazole market is expected to remain stable in volume but face continued price suppression due to intense competition.
• Future growth for lansoprazole is limited, primarily driven by steady demand for cost-effective acid suppression and potential niche roles in combination therapies.

Frequently Asked Questions

1. Are there any new indications for Prevacid currently under development? No significant new indications for lansoprazole are currently in active clinical development pipelines.
2. What is the expected lifespan of generic lansoprazole in the market? Generic lansoprazole is expected to remain a widely available and prescribed medication for the foreseeable future, given its established efficacy and cost-effectiveness for treating acid-related disorders.
3. How does lansoprazole compare to other proton pump inhibitors in terms of market share? Lansoprazole holds a significant market share within the PPI class, particularly in terms of unit volume, but its value share is lower than some newer or branded PPIs due to intense generic pricing.
4. What are the main reasons for the decline in branded Prevacid sales? The primary reason for the decline in branded Prevacid sales is the expiration of its key patents, leading to the market entry of numerous lower-cost generic versions.
5. Are there any emerging safety concerns associated with lansoprazole that could impact its future market? While all PPIs are subject to ongoing safety surveillance, lansoprazole has not been a primary focus of significant emerging safety concerns in the same way ranitidine was due to NDMA impurities. General PPI class effects (e.g., potential for bone fractures, C. difficile infection with long-term use) are well-documented and managed through prescribing guidelines.

Citations

[1] U.S. Patent 4,628,098. (1986). Pyrrole derivatives and their salts. Takeda Chemical Industries, Ltd. [2] Various generic drug approval filings with the U.S. Food and Drug Administration (FDA). (Ongoing). [3] Pharmaceutical market research reports. (2023-2024). Various industry analysis firms. [4] ClinicalTrials.gov database. (Searched 2024). National Institutes of Health.